Market Access & Pull-Through Support for Pharmaceutical Companies

Cheemia provides insight-led market access and pull-through support for pharmaceutical companies across the UK. We combine deep NHS system knowledge with targeted key account management to prioritise the right NHS organisations to achieve formulary access and drive sustainable adoption by clinicians and decision-makers.

Why NHS access is harder than it looks

Are you struggling to get your product listed, or finding that listing hasn’t translated into prescribing? You’re not alone. Many pharmaceutical companies face these challenges, even with strong clinical evidence.

Formulary submissions stall. Uptake varies by region. Sales teams spend months criss-crossing the country without clear results. Often, the issue isn’t awareness, it’s alignment.

We don’t help you sell to the NHS. We help the NHS buy from you.

Before pursuing NHS formulary listing or market access pull-through activity, we first assess whether, and where, a product can genuinely succeed within NHS systems.

As independent market access and pull-through specialists, Cheemia supports NHS decision-making and formulary access in a way that reflects how the system actually works.

Pharmaceutical market access support, built around NHS priorities

Our approach starts with a simple principle: we only work with products that genuinely address an NHS need.

That means we don’t act as traditional sales agents. We act as a trusted strategic advisor between pharmaceutical companies and the NHS, shaping propositions that reflect how the NHS actually makes decisions.

By aligning brand value with NHS priorities, we help:

This alignment-first approach is why NHS stakeholders trust us, and why our clients see meaningful pull-through rather than superficial activity.

How we support NHS formulary listing and pull-through

Our market access and pull-through service supports you through the NHS formulary process, with practical advice tailored to your product and the NHS stakeholders involved in formulary decision-making.

We help clients focus time and investment where meaningful NHS adoption is achievable to avoid pursuing routes that are unlikely to deliver a return.

The NHS is not a single system, and approaches that work in one nation do not always translate to another. Our team works across NHS England, NHS Scotland, NHS Wales and NHS Northern Ireland, with a clear understanding of the regional differences involved in formulary decision-making.

Together, they support the shaping of value propositions, local formulary submissions, and engagement with the clinicians and system stakeholders involved in supporting applications.

The insight we gather through NHS engagement feeds directly back into your strategy, messaging and market access planning. This ensures decisions are shaped by how the system is actually responding, not just by assumptions made upstream

Why Cheemia is different

Many pharmaceutical market access consultancies focus on activity. Cheemia focuses on doing the right work, for the right products, within NHS systems.

Alignment-first approach:

we only work with products that address clear NHS priorities

Independent market access specialists:

we provide independent, evidence-based advice to both pharmaceutical companies and NHS stakeholders

Four nations expertise:

we support market access activity across England, Scotland, Wales and Northern Ireland, with a clear understanding of how decision-making differs across systems

Partnership-led implementation:

we work side-by-side with NHS teams to turn access decisions into real-world uptake, supporting pathway change, service readiness and practical delivery

Focused, purposeful engagement:

we concentrate effort on the people and processes involved in formulary consideration, rather than volume of activity

We engage Medicines Management teams, ICB-level stakeholders and system leaders only when we have something of genuine value to contribute, which is why these audiences are open to working with us.

We are selective about who we work with because credibility with the NHS matters. Our work is built around long-term alignment, not transactional wins.

Who this service is for

Our pharmaceutical market access UK service is best suited to:

We focus on achieving sustainable NHS adoption built on clinical value and system alignment, rather than short-term promotional activity. If your priority is achieving NHS access built on genuine value and alignment with system needs, we should talk.

Proven outcomes, not promises

Explore real examples of how we work in our market access case studies, or hear directly from clients through our testimonials.

Understanding NHS behaviour, not just data

A pharmaceutical company identified a group of Integrated Care Boards (ICBs) as priority accounts based on market potential. Our team layered this with real-world knowledge of how those ICBs actually behave — including budget cycles, decision-making patterns and readiness to change — and refocused effort on those most likely to move.

This delivered earlier traction and avoided months of unproductive activity.

Recognising when access is structurally blocked

A company launching a branded generic was struggling to gain traction in Scotland despite formulary inclusion. We identified that national pricing and prescribing rules meant the product would be automatically substituted regardless of promotion.

We advised the client to redirect investment, saving time and budget while refocusing on markets where adoption was achievable.

Aligning product value to NHS priorities

A pharmaceutical company had a product with strong environmental benefits but limited commercial traction. We identified alignment with NHS sustainability priorities and supported senior-level engagement to reposition the product accordingly. This created a new route to influence beyond traditional formulary processes and opened doors that had previously been closed.